OBJECTIVE: To observe effect of Liuweibuqi Capsule, a Traditional Chinese Medicine(TCM), on the janus kinase(JAK)/signal transducer and activator of transcription(STAT) pathway and matrix metalloproteinases(MMPs) in a...OBJECTIVE: To observe effect of Liuweibuqi Capsule, a Traditional Chinese Medicine(TCM), on the janus kinase(JAK)/signal transducer and activator of transcription(STAT) pathway and matrix metalloproteinases(MMPs) in a chronic obstructive pulmonary disease(COPD) rat model with lung deficiency in terms of TCM's pattern differentiation.METHODS: Rats were randomly divided into a normal group, model group, Liuweibuqi group, Jinshuibao group, and spleen aminopeptidase group(n=10). Aside from the normal group, all rats were ex-posed to smoke plus lipopolysaccharide tracheal instillation to establish the COPD model with lung deficiency. Models were established after 28 days and then the normal and model groups were given normal saline(0.09 g/kg), Liuweibuqi group was given Liuweibuqi capsule(0.35 g/kg), Jinshuibao group was given Jinshuibao capsules(0.495 g/kg), and the spleen group was given spleen aminopeptidase(0.33 mg/kg), once a day for 30 days. Changes in symptoms, signs, and lung histology were observed. Lung function was measured with a spirometer. Serum cytokines were detected using enzyme-linked immunosorbent assay, and changes in the JAK/STAT pathway, MMP-9, and MMPs inhibitor1(TIMP1) were detected by immunohistochemistry, RT-PCR, and western blotting, respectively.RESULTS: Compared with the normal group, lung tissue was damaged, and lung function was reduced in the model control group. Additionally, the levels of interleukin(IL)-1β, γ interferon(IFN-γ), and IL-6 were higher, while IL-4 and IL-10 were lower in the model control group than those in the normal group. The expressions of JAK1, STAT3, p-STAT3,and MMP-9 m RNA and protein in lung tissue were higher, and TIMP1 m RNA and protein was lower in the model group compared with the normal group.After treatment, compared with the model group,the expression of inflammatory cytokines was lower in each treatment group, and expressions of JAK/STAT pathway, MMPs were lower. Compared with the positive control groups, the Jinshuibao and spleen aminopeptidase groups, lung function was better, and JAK1, STAT3, and p-STAT3 protein were lower and TIMP1 was higher in the Liuweibuqi group.CONCLUSION: Liuweibuqi capsules can improve the symptoms of COPD possibly by regulating the expression of the JAK1/STAT3 pathway and MMP9/TIMP1.展开更多
文摘目的:比较基部计划剂量补偿(BDPC组)和冷热点控制(HCSC组)两种计划优化方法得到的肺癌调强放疗计划的剂量学差异。方法:选取13例肺癌患者,采用相同优化条件分别设计BDPC和HCSC两组放疗计划。计划处方:PGTV为60 Gy/26 f、PCTV为50 Gy/26 f。比较两组肿瘤靶区和危及器官的各项剂量评价参数、计划时间和机器跳数(MU)。采用配对t检验或非参数检验进行统计学分析。结果:BDPC组相对于HCSC组有较好的靶区CI(PGTV:0.66±0.14 vs 0.58±0.15,P<0.05;PCTV:0.61±0.28 vs 0.57±0.27,P=0.066)和HI(PGTV:0.08±0.02 vs 0.11±0.05,P<0.05;PCTV:0.23±0.03 vs 0.27±0.03,P<0.05);前者较后者重要危及器官的剂量低,食管的Dmax、双肺的V5 Gy和V20 Gy分别为(59.92±2.87)Gy vs(62.09±3.34)Gy、49%±18%vs 51%±11%和22%±9%vs 24%±7%,P值均小于0.05。结论:对于肺癌调强放疗计划,BDPC优化方法得到的计划剂量分布较HCSC优化方法更优,能保证靶区覆盖的同时降低重要危及器官的受照剂量,可在临床上推广应用。
基金Supported by The National Natural Science Foundation Project:Study on the Metabolism of Chronic Obstructive Pulmonary Disease Pulmonary Qi Deficiency Syndrome and Cerebral Cortex Correlation Spectrum(No.81072781)
文摘OBJECTIVE: To observe effect of Liuweibuqi Capsule, a Traditional Chinese Medicine(TCM), on the janus kinase(JAK)/signal transducer and activator of transcription(STAT) pathway and matrix metalloproteinases(MMPs) in a chronic obstructive pulmonary disease(COPD) rat model with lung deficiency in terms of TCM's pattern differentiation.METHODS: Rats were randomly divided into a normal group, model group, Liuweibuqi group, Jinshuibao group, and spleen aminopeptidase group(n=10). Aside from the normal group, all rats were ex-posed to smoke plus lipopolysaccharide tracheal instillation to establish the COPD model with lung deficiency. Models were established after 28 days and then the normal and model groups were given normal saline(0.09 g/kg), Liuweibuqi group was given Liuweibuqi capsule(0.35 g/kg), Jinshuibao group was given Jinshuibao capsules(0.495 g/kg), and the spleen group was given spleen aminopeptidase(0.33 mg/kg), once a day for 30 days. Changes in symptoms, signs, and lung histology were observed. Lung function was measured with a spirometer. Serum cytokines were detected using enzyme-linked immunosorbent assay, and changes in the JAK/STAT pathway, MMP-9, and MMPs inhibitor1(TIMP1) were detected by immunohistochemistry, RT-PCR, and western blotting, respectively.RESULTS: Compared with the normal group, lung tissue was damaged, and lung function was reduced in the model control group. Additionally, the levels of interleukin(IL)-1β, γ interferon(IFN-γ), and IL-6 were higher, while IL-4 and IL-10 were lower in the model control group than those in the normal group. The expressions of JAK1, STAT3, p-STAT3,and MMP-9 m RNA and protein in lung tissue were higher, and TIMP1 m RNA and protein was lower in the model group compared with the normal group.After treatment, compared with the model group,the expression of inflammatory cytokines was lower in each treatment group, and expressions of JAK/STAT pathway, MMPs were lower. Compared with the positive control groups, the Jinshuibao and spleen aminopeptidase groups, lung function was better, and JAK1, STAT3, and p-STAT3 protein were lower and TIMP1 was higher in the Liuweibuqi group.CONCLUSION: Liuweibuqi capsules can improve the symptoms of COPD possibly by regulating the expression of the JAK1/STAT3 pathway and MMP9/TIMP1.
